Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition

Abstract

Oral administration of tumour cells induces an immune hypo-responsiveness known as oral tolerance. We have previously shown that oral tolerance to a cancer is tumour antigen specific, non-cross-reactive and confers a tumour growth advantage. We investigated the utilisation of regulatory T cell (Treg) depletion on oral tolerance to a cancer and its ability to control tumour growth. Balb/C mice were gavage fed homogenised tumour tissue – JBS fibrosarcoma (to induce oral tolerance to a cancer), or PBS as control. Growth of subcutaneous JBS tumours were measured; splenic tissue excised and flow cytometry used to quantify and compare systemic Tregs and T effector (Teff) cell populations. Prior to and/or following tumour feeding, mice were intraperitoneally administered anti-CD25, to inactivate systemic Tregs, or given isotype antibody as a control. Mice which were orally tolerised prior to subcutaneous tumour induction, displayed significantly higher systemic Treg levels (14% vs 6%) and faster tumour growth rates than controls (p<0.05). Complete regression of tumours were only seen after Treg inactivation and occurred in all groups - this was not inhibited by tumour feeding. The cure rates for Treg inactivation were 60% during tolerisation, 75% during tumour growth and 100% during inactivation for both tolerisation and tumour growth. Depletion of Tregs gave rise to an increased number of Teff cells. Treg depletion post-tolerisation and post-tumour induction led to the complete regression of all tumours on tumour bearing mice. Oral administration of tumour tissue, confers a tumour growth advantage and is accompanied by an increase in systemic Treg levels. The administration of anti-CD25 Ab decreased Treg numbers and caused an increase in Teffs. Most notably Treg cell inhibition overcame established oral tolerance with consequent tumor regression, especially relevant to foregut cancers where oral tolerance is likely to be induced by the shedding of tumour tissue into the gut.

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer

“…It is constitutively expressed on the surface of many Tregs, making it a target for monoclonal antibody development. This strategy has shown promise in preclinical studies in a variety of cancer types [114–116], but clinical studies have shown mixed results. In a trial of metastatic melanoma patients treated with anti-CD25 mAb in combination with a dendritic cell vaccine, activated effector T-cells expressing CD25 were depleted in addition to the targeted Tregs, potentially contributing to a lack of observed clinical responses [114].…”

Strategy to targeting the immune resistance and novel therapy in colorectal cancer

“…[150,151] L19mTNF in combination with IL-2, or with gemcitabine NK/DC crosstalk stimulates DCs to promote Th cell proliferation and maturation, which in turn "license" cytotoxic T cells (Tc), which are the final effectors. This NK-DC-Th-Tc mechanism could also be functional when L19mTNF is used in combination with IL-2, or with gemcitabine, and could provide clues for sensitizing resistant tumors to immune checkpoint blockade therapy [191][192][193] Bevacizumab combined with ipilimumab Bevacizumab combined with ipilimumab increased CD163+ dendritic cell trafficking and and CD8+ T-cell trafficking across the tumor vasculature beyond what was achieved via ipiliumumab alone [178] W. Gang et al Targeting immune resistance for CRC therapy potential predictive factors in MSS patients have been ignored. To date, the predictive role of the differential expression of PD-1 and PD-L1 has not been completely clarified, although some evidence suggests that high expression correlates with a better immunotherapy efficacy.…”

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches

“…One therapeutic approach that has shown promise in depleting T reg s from the tumor microenvironment of mouse models of carcinoma is the use of depleting antibodies targeting CD25 [ 95 ]. However, recent clinical reports have demonstrated that depletion of activated, CD25 + effector T-lymphocytes occurs along with depletion of CD25 + T reg s in patients treated with anti-CD25 mAb along with a DC-based tumor vaccine [ 96 ].…”